Please login to the form below

Not currently logged in
Email:
Password:

Breast cancer drug showing strong performance

Roche has revealed that studies into ibandronic acid have shown it could help prevent crippling bone breaks and injuries in women taking anastrozole, a crucial breast cancer treatment
Roche has revealed that studies into ibandronic acid have shown it could help prevent crippling bone breaks and injuries in women taking anastrozole, a crucial breast cancer treatment.

Anastrolzole is an efficacious and well-tolerated therapy option for breast cancer but use of it is linked with a reduction in bone mineral density (BMD), which raises the risk of fractures. Data from studies were presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

"Anastrolzole is an important therapy for breast cancer patients but we clearly want to reduce their risk of declining bone density and resultant fractures and osteoporosis," said Dr Jim Lester, lead study investigator at the Cancer Research Centre, Weston Park Hospital in Sheffield. "The results are very reassuring as they show that the strengthening effect of monthly ibandronate at the spine and at the hip is maintained after two years."

The Aribon study assessed the impact of ibandronic acid on post-menopausal patients with early breast cancer taking anastrolzole. Results indicate that, taken as a one-a-month dose, ibandronic acid significantly increases BMD and prevents bone loss in patients with osteopenic, which is a mild thinning of the bones.

Lester said that the treatment option "offers a promising solution for physicians prescribing anastrolzole to breast cancer patients."

3rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics